Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: An Indian perspective

Srivastava, Manjita; Rungta, Sumit; Dixit, Vinod Kumar; Shukla, S.K.; Singh, Tej Bali; Jain, Ashok Kumar

doi:10.1016/j.antiviral.2013.08.020

Cited by 21 publications

(25 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are recent reports that showed entecavir efficacy in west and south Asian patients [15][16][17][18][19][20]. Tenofovir has been also studied in HBV-infected patients with cirrhosis [16,[20][21][22]. Patients with decompensated cirrhosis are prone to more risk of drug adverse effects.…”

Section: Discussionmentioning

confidence: 97%

Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis

Goyal

Dixit

Shukla

et al. 2015

Indian J Gastroenterol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis

Goyal

Dixit

Shukla

et al. 2015

Indian J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…148 High baseline Child-Pugh or MELD scores are predictors of poor survival meaning that the disease may have progressed beyond the point of no return. 58,[148][149][150] In contrast, an improvement in MELD or Child-Pugh score early on-treatment is highly predictive of transplant-free survival. 1,148,149 Undetectable HBV DNA levels can be achieved in [80% after 1 year of treatment, and are associated with a lower risk of HCC development.…”

Section: Recommendationsmentioning

confidence: 95%

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Lampertico¹,

Agarwal²,

Berg³

et al. 2017

Journal of Hepatology

4,032

3,081

View full text Add to dashboard Cite

“…6 Lately, proportion of HBeAg positive patients with normal or minimally elevated ALT has been shown to have significant fibrosis and necro-inflammation in liver histology. [7][8][9] Early detection of significant liver disease and treatment substantially improves patient outcomes even after decompensation occurs 10 ; however, current clinical practice based on noninvasive tests often fails to detect liver disease until it is at an advanced stage. 11 Evidence for doing invasive liver biopsy in patients with normal liver biochemistry is not robust at present.…”

Section: H Epatitis B Virus (Hbv) Infection Remains a Seriousmentioning

confidence: 99%

HBsAg Level as Predictor of Liver Fibrosis in HBeAg Positive Patients With Chronic Hepatitis B Virus Infection

Goyal

Jain

Dixit

et al. 2015

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Background and aims: Preliminary data suggests lower serum hepatitis B surface antigen level is associated with more severe liver fibrosis in HBeAg positive patients. We evaluated the association of HBsAg level with biochemical, virological, and histological features in asymptomatic patients with chronic HBV infection. Methods: HBsAg levels were measured at baseline in 481 asymptomatic, treatment naive patients with chronic HBV infection. Subjects were followed-up prospectively (median, 12; range, 8-36 months). Phases of HBV infection were defined after regular monitoring of HBV-DNA and transaminases. Liver histology was scored using the METAVIR system. Results: HBeAg positive (n, 126) patients were significantly younger than HBeAg negative (n, 355), median age 26 vs 30 years; P < 0.01. HBV genotype could be determined in 350 patients, 240 (68.57%) had genotype D and 100 (28.57%) had genotype A. HBsAg level had modest correlation with serum HBV DNA(r = 0.6 vs 0.4 in eAg positive & negative respectively). HBeAg + ve patients with fibrosis score ! F2 showed significantly lower median serum HBsAg levels and serum HBV DNA levels compared with patients with F0-F1 score (median, range; 4.51, 2.99-6.10 vs 5.06, 4.13-5.89, P < 0.01) and (8.39, 3.85-10.60, P < 0.01) respectively. Significant inverse correlation of HBsAg level was found with liver fibrosis in eAg positive group (r = À0.76; P < 0.001). HBsAg level cut off value 4.7 log 10 IU/ml predicted moderate to advance fibrosis (F ! 2) with 92% sensitivity, 85% specificity & 91% negative predictive value. Conclusion: Lower HBsAg level might reflect the status of advanced liver fibrosis in HBeAg positive chronic hepatitis B subjects. ( J CLIN EXP HEPATOL 2015;5:213-220)

show abstract

Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: An Indian perspective

Cited by 21 publications

References 28 publications

Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis

Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

HBsAg Level as Predictor of Liver Fibrosis in HBeAg Positive Patients With Chronic Hepatitis B Virus Infection

Contact Info

Product

Resources

About